Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil by Quarter
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil: 17.0% in Q2 2026, down 18.0 pts from a year earlier.
Where the Q2 2026 figure comes from
“|| Delstrigo | 75 | 101 | 176 | 67 | 83 | 150 | 77 | 79 | 306 | 21 | 17 | 17 | 10”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 17.0% | -18.0 pts | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 9.0% | -20.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 13.0% | – | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 35.0% | +12.0 pts | Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 29.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 23.0% | – | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 30.0% | – | Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗ |
Cite this data
StockData. (2026). Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-delstrigo-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.